INDICATIONS AND USAGE
OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% is added to ophthalmic irrigating
solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining
pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.
IMPORTANT SAFETY INFORMATION
OMIDRIA must be added to irrigating solution prior to intraocular use.
OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.
Systemic exposure of phenylephrine may cause elevations in blood pressure.
Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic
acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have
a past medical history of asthma.
The most commonly reported adverse reactions at ≥2% are eye irritation, posterior capsule
opacification, increased intraocular pressure, and anterior chamber inflammation.
Please see the Full Prescribing Information for OMIDRIA at www.omidria.com/prescribinginformation.
You are encouraged to report Suspected Adverse Reactions to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Reference: 1. OMIDRIA [package insert]. Seattle, WA: Omeros Corporation; 2017.
Visit www.omidria.com
OMEROS®, the OMEROS logo®, OMIDRIA®, the OMIDRIA logo®, and
OMIDRIAssure® are registered trademarks of Omeros Corporation.
© Omeros Corporation 2018, all rights reserved. 2018-013
THE POWER OF
PREEMPTION
OMIDRIA® is the first and only
FDA-approved drug that provides
continuous intracameral delivery
of NSAID and mydriatic/anti-miotic
therapy during cataract surgery
1
• Beginning October 1, 2018,
OMIDRIA use in cataract and lens
replacement surgery for patients
with Medicare Part B coverage
will be separately reimbursed
for an additional 2 years
Coming October 1, 2018—Reinstatement of separate payment under
Medicare Part B extends the benefit of OMIDRIA to more patients.
• Centers for Medicare &
Medicaid Services (CMS)
reimbursement will be
managed under the same
procedures that were in
effect through 2017
• Omeros continues to
support access to
OMIDRIA through the
OMIDRIAssure® Patient
Assistance Program
Omeros does not guarantee reimbursement by any third-party payer. To be eligible for the
"Equal Access" Patient Assistance Program, patients must be enrolled in OMIDRIAssure prior to
surgery. For any patient for whom your facility received a free vial through the "Equal Access"
Patient Assistance Program, the patient's insurance carrier(s) should not be billed for OMIDRIA.
OMIDRIAssure program services are subject to change without notice.
